Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–280 of 280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 2, Placebo Group Clear all
Completed Phase 2 Interventional Results available

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

NCT03835117
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Wide-spectrum nutritional supplement, Placebo
Drug · Other
Lead sponsor
Rossignol Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Program for Alleviating and Resolving Trauma and Stress 2

NCT05095428
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
PARTS Program, NBSR-T Program
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 15, 2026, 7:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 15, 2026, 7:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

NCT02470403
View directory record Official record
Conditions
Elevated Body Mass Index
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 15, 2026, 7:49 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

NCT03487731
View directory record Official record
Conditions
Facetogenic Back Pain, Back Pain
Interventions
Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo
Biological · Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 15, 2026, 7:49 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

NCT06349473
View directory record Official record
Conditions
Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions
SR604, Placebo
Drug
Lead sponsor
Equilibra Bioscience LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
9
States / cities
Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 15, 2026, 7:49 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Simethicone as Part of ERAS in Bariatric Surgery Patients

NCT06812832
View directory record Official record
Conditions
Simethicone, Bariatric Surgery, Post-operative Pain
Interventions
Simethicone 80 MG, Placebo
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

NCT06122714
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144 Part A, AZD4144 Part B, Placebo Part A, Placebo Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 15, 2026, 7:49 AM EDT
Terminated Phase 2 Interventional

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT06237309
View directory record Official record
Conditions
Heart Failure
Interventions
REGN5381, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 15, 2026, 7:49 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Not applicable Interventional Results available

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

NCT01408901
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF)
Behavioral · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 15, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

NCT05891236
View directory record Official record
Conditions
Malaria
Interventions
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Biological · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 7:49 AM EDT